Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rEECur trial for recurrent or primary refractory Ewing sarcoma
ISRCTN36453794Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Dec 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in Ewing sarcoma and Ewing-like sarcoma comparing High-dose ifosfamide with High-dose ifosfamide + lenvatinib (2 arms). Primary endpoint: Event-free survival. Started Dec 2014; status: recruiting.
02
Drugs
ifosfamidelenvatinib
03
Conditions
Ewing sarcomaEwing-like sarcoma
Beyond the preview
Go deeper on ISRCTN36453794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN36453794.